Medicine Introduction Center

Posts Tagged ‘market’

AMNOG (Arzneimittelmarktneuordnungsgesetz) – Law on realignment of the pharmaceutical market in Germany

On January 1, 2011 the law regulating the reimbursement of drugs within the Germany’s statutory health care system (Neuordnung des Arzneimittelmarktes [AMNOG]) came into force.

The AMNOG allows for early assessment of the benefit of a medicinal product. Shortly after regulatory approval of a new medicinal product the “Gemeinsame Bundesausschuss” (G-BA; the Joint Federal Committee is the paramount choice-making body of the joint self-governing body of physicians, dentists, hospitals and health insurance companies in Germany) will analyse whether the new medicinal product shows additional benefit in comparison to a corresponding established therapy. Similar procedures have been introduced in many other European countries already.

It is plotted that the marketing authorisation holder (MAH) of a medicinal product can submit an application for the assessment of a potential additional benefit. To do so the MAH will provide the G-BA with a cost-benefit dossier (the value dossier “Erstattungsdossier”) and the G-BA or upon assignment the the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit in Gesundheitswesen: IQWIG) will conduct a comparative assessment of the additional benefit within 6 months. Based on the results existing or missing additional benefit will be determined.

In future there will be two institutions such as in various other EU countries: on one hand the competent authority for marketing authorisation (the BfArM and the PEI) deciding on the benefit risk ratio, i.e. the principle benefit of a medicinal product and on the other hand the authority deciding (G-BA as the choice making body) on the additional benefit (“Zusatznutzen”) ompared to existing therapies.

The new procedure of reimbursement

Following the marketing authorisation, the company will determine the price for new and innovative medicines for the first year after launch. During the first year the G-BA assesses whether the product offers an additional benefit or not. If an additional benefit has been established, the price of the new medicine will be negotiated between the Federal Association of the health insurance funds and the company. In the case that no additional benefit could be determined, the new medicine will be part of the fixed price system (“Festbetragsystem”) in accordance to their pharmacological profile.

The benefit analysis

]]>

Each medicinal products with new active substances which are launched for the first time will be assessed based on the “value dossier” prepared by the MAH. This dossier has to be submitted at latest at the time of marketing. This dossier includes information on the approved indication(s), on the benefit/risk and additional benefit in comparison to established therapies, on the target patient group(s), the costs of therapy for the health assurance funds. The company has to prove that there is an additional benefit. The evidence will be based on clinical studies conducted for the registration dossier. If applicable, additional special studies may have to be conducted as discussed with the G-BA and IQWIG.

It will be possible to meet with the G-BA prior to the submission of the dossier to discuss aspects of the products and the benefit for the patients and specific patient groups.

At the moment it is not clear how studies will have to be designed to examine the additional benefit. The endpoints based on which the assessment will be performed will probably differ from those used to investigate the benefit risk. Surrogate parameters may play a larger role when assessing the additional benefit as compared to conventional studies performed for registration.

The dossier is assessed by IQWIG and G-BA in a 6 month process. G-BA will choose on the additional benefit.

If rejected, the MAH can submit a new application to assess an additional benefit only one year after the first procedure.

The individual indications of a medicinal product will be analysed sequentially.

Agreement between the company and the health insurance funds

If a new medicinal product is not part of the fixed price system (“Festpreis”) the company will negotiate the price with the central federal association of health insurance funds (Spitzenverband der Krankenkassen). This will be done based on the benefit analysis and the cost-benefit analysis of the G-BA in accordance with the principles of quality, cost-effectiveness and the price of the medicinal product in other countries. The agreement can only be cancelled after one year.

If no agreement is reached there is an arbitration procedure. Both parties as well as independent members will be part of the arbitration committee (§ 130b Abs. 4 SGB V).

Cost-effectiveness assessment

After the arbitration committee has reached a choice, the party concerned can questioned for a cost-effectiveness analysis. In this case the G-BA will question the IQWIG to perform the analysis. This analysis will be based on clinical studies and will take a maximum of 3 years.

Agreement between the companies and individual insurance companies

Individual insurance agencies can enter into agreements with companies which differ from the established price; i.e. the insurance agencies can negotiate discounts. The physicians will have access to this information.

In the future the same regulations will apply for the private health insurance companies (Private Krankenversicherungen, PKV)

Orphan drugs

The regulations with regard to value dossier and reimbursement agreements are not applicable to orphan drugs. Since an orphan drug will only be approved for a rare disease with lack of adequate treatment, no evidence of additional benefit needs to be provided.

But, if the business volume of the orphan drug reaches 50 million EUR during 12 months then the additional benefit will have to be provided and a value dossier will have to be submitted.

In case indications outside the orphan diseases will be approved a procedure to determine additional benefit will have to be initiated.

Shopsters Vision: The future treatment of orphan diseases – market forecasts for 2015, analysis and reimbursement
leading provider of business intelligence

, launched its latest study “The future of therapy for rare diseases – market forecasts for 2015, analysis and reimbursement” The report provides a thorough analysis unmet needs, drivers and barriers that affect the treatment of diseases of the global market for orphans. The report analyzes the markets for therapeutic orphan diseases in the United States, the first five European countries (UK, Germany, France, Italy and Spain) and Japan. The ways of dealing with the use, sale and the price is expected to 2015 for key geographic areas and to select therapeutic segments. The report also provides a benchmarking of leading companies, and also covers mergers, acquisitions and licensing agreements that shape the global marketplace.

/>
This report draws on data and information from proprietary databases, the primary and secondary research and analysis of the home by GBI investigation team of experts industry.

Field

The scope of this report includes:
– The annualized market for orphan diseases treatment market in 2000 to 2008, forecasts />
-. The analysis of therapeutic geographies orphan disease market in the world, including USA, UK, Germany, France, Italy, Spain and Japan br – characterization of the market the market of orphan diseases therapies including market size, the annual cost of treatment methods and treatment using />
– Coverage of pipeline molecules at various stages drug development
– companies leading benchmarking. Large companies studied in this report are Roche Farma, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc. and Shire Pharmaceuticals PLC
Actelion -. Main activities M & A, licensing agreements, which took place between 2008 and 2009 the global market for therapeutic orphan diseases

Reasons to buy

The report will improve their choice making. This will
– Align portfolio of products to market
with high growth potential – develop market access and market expansion strategies by identifying key therapeutic segments and geographic markets ready
to strong growth – Strengthen R & D pipeline by identifying new target mechanisms that can produce first class of molecules with greater efficiency and safety
– Develop key strategic initiatives by understanding the main areas of interest of the leading companies
– Exploit of licenses and licensing opportunities by identifying products that would fill gaps in the portfolio mentioned

Roche Pharma , Genzyme Corporation

Novartis AG Celgene Corporation

Orphan Europe Pfizer Inc.

Actelion Pharmaceuticals Shire Plc.

Contents

1 Contents 1.1 List

Tables 1.2 List of Figures
2 global market orphan diseases
Introduction 2.1 Description of the disease
2.1.1 The United States

States 2.1.2 Europe 2.1.3 Japan

Report 2.3 Overview 2.2 Market orientation 3
World Orphan Disease Therapeutics Market: Market characterization

3.1 3.2 Market Forecast by orphan disease sector
3.3 usage patterns
ill population 3.3.1 3.3.2

Seeking Diagnosis Treatment Population Population Population 3.3.4 3.3.3 recipe

3.3 0.5 Templates therapeutic

Drivers 3.4 Market Shares 3.4.2 Market Constraints 3.4.1 Geographical

3.5 Key market trends 3.5.1 Increase

portfolio of federal funds 3.5.2 3.5.3
regulatory trends – current price and the redemption scenario
World Fabry Disease Therapeutics Market Overview 4 4.1

Market 4.2 Market Forecasts 4.3 Cost
therapy averaged 4.4

4.4.2 4.4. a research treatment





Fabryzyme 4.5.2 4.5 0.1 6.4 Replagal Drug Pipeline

5 Global analysis of Pompe disease
markets Therapeutics Market 5.1 Overview 5.2

5.3 The forecast cost of the market average of 5.4 />

5.4.1 5.4.2 populations of sick people seeking treatment


order 5.4.4 Patterns of the population of the therapeutic use of products 5.4.5
Myozyme 0.1 5.5 5.5 Analysis

6 MPS 5.6 Pipeline VI World Disease Therapeutics Market
market 6.1 Overview 6.2

average market forecast of 6.3 Cost of therapy
6.4 usage patterns

6.4.2 6.4.1 of sick of people being treated for

Diagnostic 6.4.3 Population 6.4.4 Population 6.4.5
habits prescription of therapeutic use
Analysis Product 6.5 6.5.1

Naglazyme 7 The United States Orphan Disease Therapeutics Market
market 7.1 Overview 7.2

market forecasts 7.3 usage patterns
7.3. a sick population
7.3.2 of the population seeks treatment
7.3.3 Population Population Diagnostics 7.3.4

7.3.5 Trends in the therapeutic use of prescription />
market 8.1 Overview 8.2

8.3 Market Forecasts usage patterns

8.3.1 Population 8.3.2
patient population seeking treatment population Diagnostics 8.3.3 8.3.4 8.3.5

population prescribing habits therapeutic
9 Japan Orpahn Disease Therapeutics Market
Market Overview 9.1 9.2

market forecasts 9.3 usage patterns

9.3.2 9.3.1 of sick people seeking treatment ” br />
Diagnostic 9.3.3 Population 9.3.4 Population 9.3.5 recipe

patterns of use of 10 therapeutic orphan disease world Therapeutics Market: Competitive Landscape

10.1 Introduction 10.2 Profile of competition
10.2.1 10.2.2 Genzyme Corporation Celgene Corporation

10.2.3 10.2.4 Actelion Pharmaceuticals Shire Pharmaceuticals

AstraZeneca 10.2.5 10.2.6 10.2.7
Boehringer Ingelheim, Bristol-Myers Squibb
10.2.8 GlaxoSmithKline (GSK), Novartis 10.2.9


02/10/10 02/10/11 10/02/12 Pfizer Eli Lilly Sanofi Aventis

02/10/13 10/02/14 UCB Pharma Wyeth
Pipeline Analysis 11 11.1

pirfenidone Rituxan 11 genetic disorders, 2
11.2. Inhalation solution Denufosol tetrasodium (INS37217)
11.2.2 Bronchitol (mannitol)
11.2.3 Catena (idebenone)

11.3 11.3.1 Infectious Diseases XP-28 (xepol)

Neurology 11.4.1 11.4.2 11.4 Cladribine Clazosentan
(Pivlaz ®) 11.5 Respiratory

11.6 Disorders Cardiovascular Transplantation 301 012 11.7 11.7.1
ISIS (sodium Mipomersen)

cancer Avastin 11.8 11.8.1 11.8.2 11.8.3

enzastaurin 8.11 4 patupilone Zactima

11.8.5 11.8.6 Genasense ipilimumab (MDX-010, MDX-101) 11.9

cancer blood cancer 10.11 11.11

12 other global orphan Therapeutics Market: Consolidation
12.1 Strategic Mergers and Acquisitions
Genzyme Corp. and Bioenvision 12.1 .1, and ViroPharma Inc.
Lev Pharmaceuticals
12.1.2 12.1.3 Biovitrum, Swedish Orphan
12.1.4 Shire plc and Zymenex A / s

12 License , 2 12.2.1 Overview 12.2.2
drug discovery and preclinical phase I

12.2.3 12.2.4 12.2.5 Phase I Phase III

13 Annex 12.2.6 Approved

13.1 13.2 Market data definitions abbreviations key support

Research Methodology 13.3 13.4

13.4.2 Coverage 13.4.1 Secondary Research 13.4.3
Primary Research 13.4.4 Forecasts

13.5 Expert Panel Validation 13.6 Contact

13.7 Waiver

For more information on this report and buy a copy please visit:
Contact:

Visionshopsters
Tel: 91-22-40583000
Email: Website marketing@visionshopsters.com
: www.visionshopsters.com

Drug online market? best place to buy medicines online

The increasing prevalence of Internet access has allowed the emergence of new online markets. Customers that is suitable for products online instead of going to the store. A market is a place where goods and services exchanged. Online drug Market is one of the emergining and vital market. A drug is now an integral part of life, as it helps people to get fit and stay clear of the disease. While some drugs required a written prescription before selling some do not require pre-written prescription.

Medicines that are in line Drug Market is one that requires no pre-written prescription. These markets provide precautionary things related to drug use in particular with the help of medical experts. Conceptions and misconceptions related to a particular drug may be authorized to discuss with experts in the market itself.

Customers can scan the entire product line and description, reviews, and the cost and you can even compare with other products. Some market also offers discounts and sales plot to promote their products. Some of them offer free shipping and free replacement offers to attract customers online. The best of the online drug market is that customers have time to look around, to seek other opinions, do research. There is no pressure to buy and the customer can consider their options carefully. And no dark alley.

Like the drug market online market there steroids available online, where you can buy steroids. But, using the access of steroids is harmful to health because it can result in bodily injury in the elderly. But in some situations the use of steroids are very useful, so if you are in need of steroids do not have to waste time and money visiting the pharmacy and question for steroids. With the help of steroids online market that are enabled to choose the best steroids and buy online. After placing an order and complete the payment you receive the product at the door of his home in the small space of time.

But, you can not trust the online marketplace steroids and the drug market in line in case of emergency, that takes some time Shipping and delivery after ordering. It may take about 4-6 days for the product arrives at your door, but if you have time for some choice and need in large quantities this online marketplace is the best choice for you.

World weight loss and diet market management (2009 – 2014)

obesity and weight problems have always been a health and fitness issues. The increased levels of awareness among the calories they consume (and concerned about their appearance), consumers have opened new avenues and opportunities in this market. The significantly higher rate of entry of new products in the segment weight control requires industry participants to adopt proactive strategies. The market growth overall weight control is not driven by the larger market segments such as fitness devices, there are additional opportunities in minor markets such as fitness accessories. This makes it more vital to know clearly the characteristics of micro-markets in order to obtain a holistic view of the industry.

While the existing reports have attempted to study the attitudes of end users and the demographics do not provide a complete picture from the perspective of the industry. This report analyzes market dynamics only from the point of view of the sector. In addition, the issue of weight management previously discussed in other reports focus only on weight loss and more often only in the food market. This report is intended to provide a two-dimensional image of the market, focusing on all aspects of weight control and weight loss are analyzed at the micro market. The report also includes segments of food and beverages, medicine and surgery, services, fitness equipment and accessories.

Thu Each segment table report will provide market drivers, constraints and opportunities, along with key players and competitive landscape. This report will also provide more than 100 tables of market for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments, such as gymnasiums, training centers for weight loss, diet and suppliers of high-calorie F and B and so on.

Market data consists of the total sales figures of all sub-markets within the weight control market. We studied more than 500 items of news and analysis of new product launches in this market. Main events in the market are derived from the profile 50 companies. Patents and investigate complaints documented in the past five years to get a thorough understanding of the usefulness of equipment and products. Secondary research is based on two sources of paid and unpaid. Primary research is conducted to provide further insight into the weight management segment.

Scope of the report

Managing long-term weight in the report refers to the weight loss, weight gain and weight maintenance. The report examines the segmentation of the market after the global weight control.

Weight Management – Food, Beverages & Substitutes Wed low-calorie prepared meals, meal substitutes, low calorie sweet, low calorie drinks, and other markets.

Weight – Drugs and Supplements Mon General obesity, prescription drugs, prescription drugs for a small time, the counter medications and supplements, cosmetics.

Weight Control Services Fri media, dietary services and consultations, alternative therapies, professional services, commercial weight loss chains of food and diet food Diet Delivery (fresh and frozen), health club industry, invasive and noninvasive methods of treatment for weight control)

Weight Management Ingredients Market Mon appetite suppressant and satiety ingredient used in food and beverage market for artificial sweeteners and other ingredients in the medications and supplements.

weight management devices and accessories on the market Wed Cardiovascular equipment, weight lifting equipment, sports equipment, home gyms and several gyms battery and accessories market)

What makes our reports unique?

1. We offer the longest string of market segmentation in the industry with our share markets, three-level analysis of a minimum of 40 micro markets collectively exhaustive and mutually exclusive.

2. We offer 10% customization to ensure that our customers find information on specific market need.

3. Each report is approximately 150 pages, with over 30 market data tables, more than 30 company profiles, and an analysis of 200 patents.

4. No single report of any other publisher provides market data for all market segments (ie, products, services, applications, components, and technology) covering the four geographical areas of North America, Europe, Asia Pacific and ROW.

5. 15 pages of high-level analysis to identify opportunities, best practices, market entry strategies, benchmarking strategies, market positioning, product positioning and competitive positioning.

Key questions answered

1. What are the high-growth segments and how the market is segmented in terms of applications, products, services, ingredients, technologies, stakeholders?

2 What are the market estimates and forecasts. the markets are doing well and not

?

3 Where are the gaps and opportunities. What factors are driving market growth

4. What are the main playing fields and the imperatives of winning tip?

5 What is the competitive landscape;. Who are the major players in each segment, what are their strategic directions, operational forces, the main product, and product pipelines? Who is doing what?

Wed powerful research and analysis

Analysts working with MarketsandMarkets from renowned publishers and market research companies worldwide, bringing their knowledge and understanding domain. Get the facts from more than 22,000 news and information sources, a huge database of key industry participants and are based on our relationships with over 900 market research companies.

World weight loss and diet market management (2009 – 2014)

obesity and weight problems have always been a health and fitness issues. The increased levels of awareness among the calories they consume (and concerned about their appearance), consumers have opened new avenues and opportunities in this market.

It Now: World weight loss and diet market management

Orignal Source: Market Research

significantly higher rate of entry of new products in the segment weight control requires industry participants to adopt proactive strategies. The market growth overall weight control is not driven by the larger market segments such as fitness devices, there are additional opportunities in minor markets such as fitness accessories. This makes it more vital to know clearly the characteristics of micro-markets in order to obtain a holistic view of the industry.

While the existing reports have attempted to study the attitudes of end users and the demographics do not provide a complete picture from the perspective of the industry. This report analyzes market dynamics only from the point of view of the sector. In addition, the issue of weight management previously discussed in other reports focus only on weight loss and more often only in the food market. This report is intended to provide a two-dimensional image of the market, focusing on all aspects of weight control and weight loss are analyzed at the micro market. The report also includes segments of food and beverages, medicine and surgery, services, fitness equipment and accessories.

Thu Each segment table report will provide market drivers, constraints and opportunities, along with key players and competitive landscape. This report will also provide more than 100 tables of market for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments, such as gymnasiums, training centers for weight loss, diet and suppliers of high-calorie F and B and so on.

Market data consists of the total sales figures of all sub-markets within the weight control market. We studied more than 500 items of news and analysis of new product launches in this market. Main events in the market are derived from the profile 50 companies. Patents and investigate complaints documented in the past five years to get a thorough understanding of the usefulness of equipment and products. Secondary research is based on two sources of paid and unpaid. Primary research is conducted to provide further insight into the weight management segment.

Scope of the report

Managing long-term weight in the report refers to the weight loss, weight gain and weight maintenance. The report examines the segmentation of the market after the global weight control.

Weight Control – Food, Beverage and Alternates

prepared low calorie meals, meal substitutes, low calorie sweet, low calorie drinks, and other markets.

Weight Management – The General

medications and supplements against obesity, prescription drugs, prescription drugs for a small time, the counter medications and supplements, cosmetics.

Weight Management Services

media, dietary services and consultations, alternative therapies, professional services, commercial weight loss chains of food and diet, diet food home delivery (fresh and frozen), health club industry, invasive and noninvasive methods of treatment for weight control)

Weight Management Ingredients Market

appetite suppressant and satiety ingredient used in food and drinks market, artificial sweeteners and other ingredients in the medications and supplements.

Weight management devices and accessories market

Cardio equipment, weight lifting equipment, sports equipment, home gyms and several gyms battery and accessories market)

What Our report makes it unique?

We offer the longest string of market segmentation in the industry with our share markets, three-level analysis of a minimum of 40 micro markets collectively exhaustive and mutually excluyentes.Ofrecemos 10% of customization ensure that our customers find information on specific market necesitan.Cada report is approximately 150 pages, with over 30 market data tables, more than 30 company profiles and an analysis of 200 patentes.No single report any other publisher provides market data for all market segments (ie, products, services, applications, components, and technology) covering the four geographical areas of North America, Europe, Asia Pacific, and ROW. 15 pages of high-level analysis to identify opportunities, best practices, market entry strategies, benchmarking strategies, market positioning, product positioning and competitive positioning.

key questions answered

What are the high-growth segments and how the market is segmented in terms of applications, products, services, ingredients, technologies, stakeholders and what are the market estimates and forecasts the markets are doing well and which not? Where are the gaps and opportunities, what factors are driving market growth and what are the main playing fields and the imperatives of winning tip? What is the competitive landscape, which are the main actors in each segment, what are the strategic guidance, operational forces, the main product, and product pipelines? Who is doing what?

Powerful research and analysis

Analysts working with MarketsandMarkets from renowned publishers and market research companies worldwide, bringing their knowledge and domain understanding. Get the facts from more than 22,000 news and information sources, a huge database of key industry participants and are based on our relationships with over 900 market research companies.

http://www.marketsandmarkets.com/Market-Reports/weight-loss-industry-224.html Pharmacy Find reports

The Future Of Cosmetic Medical Device Market By 2016 – the market to regain a positive growth of
GBI

Research new report, “The future of the aesthetic device market in 2016 – the market to regain positive growth,” provides key data, information and analysis on the global aesthetic devices market, a key segment in the industry medical equipment. This report provides medical device market outlook, competitive landscape and market trends information in three categories of aesthetic medical device market – Laser Aesthetics and power devices, facial and breast implants. The report provides an overview of key trends affecting this category, and analytical content key in the dynamics of the market. The report also examines the competitive landscape, key pipeline products and technology offerings.

This report builds on data and information from proprietary databases, primary and secondary research and analysis of the home by GBI investigation team of industry experts. Scope

• Key geographies including the U.S. (United States), Japan, France, the United Kingdom (UK), Germany, Italy and Spain
• Size of global market and company data shared by three categories aesthetic medical device market -. Cosmetic lasers and energy devices, facial and breast implants.
• annualized market data revenues for 2009, forecasting the progress of 7 years to 2016. Update company stock data for 2009.
• Qualitative analysis of key market trends, market drivers and restrictions on categories and segments.
Company profiles • competitive landscape and key. Major players covered include Allergan, Mentor Corporation, Sientra, Medicor, Cynosure, Lumenis, Syneron, Candela, Palomar Medical, Cutera, Solta Medicine, and medical QMed Bioform.
• Insert conduit products and technologies expected to reach the global market for aesthetic medical devices in the near future.

Reasons to buy • Develop business strategies through an understanding of trends and developments that are driving the market for aesthetic medical devices worldwide.
• Design and development of its product development, marketing and sales strategies.
• Take advantage of opportunities for mergers and acquisitions by identifying market players with the most innovative pipeline.
• Develop market entry and market expansion strategies.
• Identify key players in a better position to exploit emerging market opportunities.
• Exploit the granting of licenses and licensing opportunities out by identifying products, most likely to ensure a solid return.
• What is the next huge thing in the medical aesthetic devices market landscape? – Identify, know and capitalize
• Make more informed business decisions after thorough and exhaustive analysis of the market for aesthetic medical devices and the factors that determine

1 Table of Contents br <. />
1.1 List of Tables 7 1.2 List

Figures 8 2 Introduction 9 2.1 Orientation Research
GBI 9

3 Aesthetics Medical Devices World: Market characterization 10 3.1 Market
Global Cosmetic Medical Devices, Forecasts Revenue ($ million), from 2009 to 2016 10 3.2
Aesthetics Medical Devices, Market Trends 10 3.3
Aesthetic Medical Device, 11 br /> market

Market 12 3.4 Global Medical Aesthetic devices, the key actions of the company, 2009 12

4 Global Medical Device Market Aesthetics: Category Analysis and Forecasts 14 4.1
Aesthetic Laser power devices 14 4.1.1
Global Cosmetic Laser and output devices energy, estimated revenue ($ m), from 2009 to 2016 14 4.1.2
Cosmetic lasers and energy devices: key market trends 4.1.3 15
Aesthetic Laser energy devices: Market Dynamics 16 4.1.4
Global Aesthetic Laser Market and Energy Devices, key company share (%) 2009 18
4.2 18 breast implants
4.2.1 Global Market breast implants, revenue forecast ($ m), from 2009 to 2016 19 4.2.2
breast implants: key market trends
19 4.2. 3 Breast implants: the dynamics of the market 20 4.2.4
silicone breast implants from the market, revenue forecasts ($ m), from 2009 to 2016 20
4.2.5 The saline breast implants market, revenue forecasts (million dollars) from 2009 to 2016 21 4.2.6 Global Market
breast implants, the key actions of the company (%) 2009 22 Facial Aesthetics
4.3 22
4.3.1 Global Market of Facial Aesthetics, the estimated revenue ($ m), from 2009 to 2016 23 4.3.2
Facial Aesthetics: key market trends 4.3.3 23
Facial Aesthetics: Market Dynamics 4.3.4 Market 24
Global Facial Aesthetics, the company’s key actions (%) 2009 24 4.3.5
hyaluronic acid, revenue forecasts (million dollars), 2009 – 2016 25
4.3.6 Polymer Particles & Dust (PPF), Forecasts of Revenue (million dollars) from 2009 to 2016 26 4.3.7
collagen products, revenue forecasts (U.S. $ million ), from 2009 to 2016 27

5 Global Medical Device Market Aesthetics: Country Analysis and Forecasts 28 5.1 The U.S.
Aesthetic Medical Devices Market 28 5.1.1 The U.S.
Aesthetic Laser devices and energy production, income ($ m), from 2009 to 2016 28 5.1.2 The U.S.
Aesthetic Laser energy production devices, the key actions of the company (%) 2009 29 5.1.3 The U.S.
Breast implants market revenues ($ m), from 2009 to 2016 30 5.1.4 The U.S.
Breast implants market, the key actions of the company (%) 2009 31
5.1.5 The U.S. market Facial Aesthetics, income ($ m), from 2009 to 2016 32
5.1.6 U.S. Market Facial Aesthetics, the company’s key actions (%) 2009 33
Market 5.2 The Japanese Aesthetic Medical Devices 33 5.2.1
Japanese aesthetic laser devices and energy production, income ($ m), from 2009 to 2016 34 5.2.2
Japanese Aesthetic Laser and market power devices, the key actions of the company (%) 2009 34 5.2.3
Japanese breast implants market revenues ($ m), from 2009 to 2016 35 5.2.4
breast implants Japanese market, the key actions of the company (%) 2009 36
5.2.5 Market Japan Facial Aesthetics, income ($ m), from 2009 to 2016 36 5.2.6 Japanese market
Facial Aesthetics, the company’s key actions (%) 2009 37 5.3
European Medical Market Aesthetic devices 37 5.3.1
European and aesthetic laser devices for energy production, income ($ m), from 2009 to 2016 38 5.3.2
European Aesthetic Laser energy production devices, the key actions of the company (%) 2009 39 5.3.3
breast implants European Market 40 5.3.4
breast implants market in Europe, the key actions of the company ( %), 2009 42
5.3.5 European Market for Facial Aesthetics
3.5 0.6 43 European Facial Aesthetic Market, the company’s key actions (%) 2009 46

6 Global Medical Device Market Aesthetic: Competitive assessment 47 6.1 Lumenis Ltd.
47

6.1.1 Products 47 6.2 47 Candela Corporation Finance 6.2.1
47

6.2.2 Products 48 6.3 Cynosure, Inc 48
48
Finance 6.3.1 3.6 0.2 6.3.3 Products 49
Cynosure Signs an Association Agreement with Unilever 49 6.4 Syneron Medical
49
50
6.4.1 Finance 6.4.2 Products 50 4.6 0.3
medical Syneron Medical to buy 51
Primaeva 6.4.4 Syneron Candela Corporation to combine 51
6.5 Cutera, Inc. 52
6.5.1 Finance 6.5.2 Products 52
52
Palomar Technologies 6.6 53
53
6.6.1 Finance 6.6.2 Products 53 6.6.3
Palomar Medical Technologies and Johnson & Johnson Complete Agreement
6.6 0.4 54 Palomar Medical Technologies Terminates Agreement with Q-Med 54
6.7 Mentor Corporation 54

6.7.1 Products 55 6.7.2 Johnson & Johnson buys Mentor Corporation 55
6.8 Allergan, Inc. 56 6.8.1
Finance 56 6.8.2 Products 57

QMed AB 6.9 57 57

6.9.1 Finance 6.9.2 Products 58
6.10 Sientra, Inc 58
6.10.1 Products 6.11 59
BioForm Medical, Inc. 59
59
6.11.1 Finance 6.11.2 Products 6.11.3 60
Merz Pharma buys BioForm Medical 60

7 devices Aesthetic Medicine World Market: Product Pipeline Analysis 62 7.1
energy Cosmetic and Laser devices
7.1.1 SANUWAVE 62: 63 evoPACE Cellulite
Asclepion Laser Technologies 7.1.2 Effect 7.1.3 Mediostar 63
Candela Corporation: Pneumatic Skin fattening (PSF) to tone the skin 63
7.1.4 Medicis Pharmaceutical Corporation: LipoSonix System 64
7.1.5 Sonovia limited: Ultrasound technology SonoRx 64
7.1.6 Medixsysteme: 64
7.1.7 SpaShape Medixsysteme: Ultracontour-U.Lift
7.2 64 breast implants 7.2.1 65-
Alure Medical: Alure Refine 65
7.2.2 Mesynthes Ltd: Unit 65 Endoform breast Allergan
7.2.3: Style Natrelle
7.2 410 65 .4 AirXpanders: patient-activated devices controlled expansion Sientra 66
7.2.5: Improve Silimed 66
7.2.6 Sientra: Silimed soft silicone gel implants Round 66
Facial Aesthetics 7.3
7.3.1 Contura 67 International: 67
7.3.2 Aquamid Serica Technologies: Silk Eplica 67
Evera Medical 7.3.3: FulFil lip implant cosmetic Increase 67
7.3.4 QMed: Macrolane 68
7.3.5 Mentor Corporation: Puragen 68
7.3.6 Allergan: Volume 68

8 Appendix 69 8.1 Definitions 69
8.1.1 Aesthetic Laser power devices 69
Breast Implants 69 8.1.2 8.1.3 Facial Aesthetics
69
69
8.2 Acronyms 8.3 Research Methodology 69
8.3.1 Secondary Research 70 8.3.2 Primary Research

8.3.3 Models 70 71 71

8.3.4 Forecasts 8.3.5 Expert Panels 71
8.4 Contact Us 71 8.5 Disclaimer 72

1.1 List of Tables Table 1
: Medical Device Market Aesthetics, total revenue, total ($ million) from 2009 to 2016 10
Table 2: Market Aesthetics Medical Devices, Global, joint stock company (%) 2009 13
Table 3: Aesthetic Laser and devices for energy, total income, general ($ m), 2009-2016

15 Table 4: Major Medical, number of practitioners, USA, 2009 17
Table 5: Aesthetic Laser Device energy production and World Share, the company (%) 2009 18
Table 6: Breast implants market, the overall revenues, general ($ m), from 2009 to 2016 Table 19
7: The silicone breast implant market, Global, ($ m), from 2009 to 2016
21 Table 8: saline breast implants Global Market, the total income ($ m), 2009 – 2016
21 Table 9: Breast implants Global Market Share of the company (%) 2009 22
Table 10: Facial Aesthetic Market, the overall revenues, general ($ m), 2009-2016
23 Table 11: Facial Aesthetic Market, Global Action, the company (%) 2009 24
Table 12: Market hyaluronic acid, the overall revenues, general ( $ m), from 2009 to 2016 25
Table 13: Particle and Polymer Fillers market, the overall revenues, general ($ m), from 2009 to 2016
26 Table 14: Market Product collagen, the overall revenues, general ($ m), 2009-2016 27
Table 15: Aesthetic Laser energy production devices, the U.S., total revenue ($ m), 2009

2016 28 Table 16: Cosmetic Laser and devices for energy, U.S., Company Share (%) 2009 29
Table 17: Market for breast implants, U.S. , total revenue ($ m), from 2009 to 2016
30 Table 18: Breast Implants Market, U.S., Company Share (%) 2009 31
Table 19: Cosmetic Market Facial, USA, total revenue ($ m), 2009-2016
32 Table 20: Facial Aesthetic Market, U.S., Company Share (%) 2009 33 Table 21
: Cosmetic Laser and power devices market, Japan, the total revenue ($ m), 2009-2016

34 Table 22: Cosmetic Laser and devices for energy, Japan, Company Share (% )
2009 35 Table 23: Breast implants market, Japan, the total revenue ($ m), from 2009 to 2016
35 Table 24: Breast Implant Market, Japan, Company Share (%) 2009 36
Table 25: Facial Aesthetic Market, Japan, the total revenue ($ m), from 2009 to 2016
37 Table 26: Facial Aesthetic Market, Japan, Company Share (%) 2009 37
Table 27: Aesthetic Laser power devices market, Europe, total revenue ($ m), 2009-2016
38 Table 28: Aesthetic Laser energy production devices , Europe and shares the company (%) 2009 39
Table 29: Market silicone breast implants, Europe, total revenue ($ m), from 2009 to 2016 40
Table 30: Market saline breast implants, Europe, total revenue ($ m), from 2009 to 2016
41 Table 31: Breast Implant Market, Europe, Company Share (%) 2009 42 Table 32
: hyaluronic acid market, Europe, total revenue ($ m), from 2009 to 2016
43 Table 33: Market polymer particles and dust, Europe, General Revenue (million dollars) from 2009 to 2016 44
Table 34: Market collagen products, Europe, total revenue ($ m), from 2009 to 2016
45 Table 35: Facial Aesthetic Market, Europe and shares the company (%), 2009
46 Table 36: Lumenis, products, applications, features and benefits,
2010 47 Table 37: Candela Corporation, Products, Applications Features and Benefits, 2010 48 Table 38
: Cynosure, Products applications, features and benefits
2010 49 Table 39: Cynosure Signs an Association Agreement with Unilever,
2009 49 Table 40: Syneron Medical, Products, applications, features and benefits, 2010 50
Table 41: Syneron Medical to buy Primaeva Medical
2009 51 Table 42: Syneron and combine Candela Corporation, 2009 51 Table 43
: Cutera, Products, Applications, Features and Benefits, 2010 52
Table 44: Palomar, products, applications, features and benefits
2010 53 Table 45: Mentor Corporation, products, applications, features and benefits
2010 55 Table 46: Johnson &, Johnson buys Mentor Corporation, 2009 55
Table 47: Allergan, products, applications, features and benefits
2010 57 Table 48: QMed, products, applications, features and benefits
2010 58 Table 49: Sientra, products, applications, features and benefits
2010 59 Table 50: BioForm Medical, products, applications, features and benefits of
2010 60 Table 51: Merz Pharma buys BioForm Medical, 2010 60
Table 52: Facial Aesthetics, new products, the 2009 World
62 Table 53: Breast implants, new products, World
2009 65 Table 54: Facial Aesthetics, new products, Global, 2009 67

1.2 List of Figures Figure 1
: Medical Device Market Aesthetics, total revenue, total ($ million) from 2009 to 2016 10
Figure 2: Aesthetics Market Medical Devices, Global, joint stock company (%) 2009 12
Figure 3: Laser Aesthetics and energy production devices, the overall revenues, general ($ m), 2009-2016
14
Figure 4: Aesthetic Laser and energy production devices and World Share, the company (%) 2009 18
Figure 5: The market for breast implants, the overall revenues, general ($ m) from 2009 to 2016 19
Figure 6: Silicone breast implants market, the overall revenues, general ($ m), from 2009 to 2016 20
Figure 7: Market saline breast implants , the overall revenues, general ($ m), from 2009 to 2016 21
Figure 8: breast implant market, Global, joint stock company (%) 2009 22
Figure 9: Facial Aesthetic Market , the overall revenues, general ($ m), from 2009 to 2016 23
Figure 10: Facial Aesthetic Market, Global, Company Share (%) 2009 24
Figure 11: Market hyaluronic acid , the overall revenues, general ($ m), 2009-2016
25 Figure 12: Particles and polymer powder market, the overall revenues, general ($ million), from 2009 to 2016 26 Figure 13
: Market for collagen, total revenue, general ($ m), from 2009 to 2016
27 Figure 14: Laser Aesthetics and energy production devices, the U.S., total revenue ($ million ), from 2009 to 2016 28
Figure 15: Cosmetic Laser and Energy Market devices, U.S., Company Share (%) 2009 29
Figure 16: The breast implant market, U.S. ., total revenue ($ m), 2009-2016
30 Figure 17: The breast implant market, the U.S., Company Share (%) 2009 31
Figure 18: Market Facial Aesthetics, the U.S., total revenue ($ m), from 2009 to 2016 32
Figure 19: Facial Aesthetic Market, U.S., Company Share (%) 2009 33 Figure
20: Aesthetic Laser energy production devices, Japan, the total revenue ($ m),
2009 to 2016 34
Figure 21: Laser Aesthetics and devices for energy, Japan, Company Share (%) 2009 34
Figure 22: Breast Implant Market, Japan, the total revenue ($ m), 2009-2016
35 Figure 23: Breast Implant Market, Japan, Company Share ( %), 2009 36
Figure 24: Facial Aesthetic Market, Japan, the total revenue ($ m), from 2009 to 2016 36
Figure 25: Facial Aesthetic Market, Japan, Company Share (%) , 2009 37
Figure 26: Laser Aesthetics and energy production devices, Europe, total revenue ($ m), 2009-2016

38 Figure 27: Laser Aesthetics and devices Energy, Europe and shares the company (%) 2009 39
Figure 28: Market silicone breast implants, Europe, total revenue ($ m), from 2009 to 2016 40
Figure 29: The saline breast implant market, Europe, total revenue ($ m), from 2009 to 2016 41
Figure 30: Breast Implant Market, Europe and shares the company (%) 2009 42
Figure 31: hyaluronic acid market, Europe, total revenue ($ m), from 2009 to 2016 43
Figure 32: Market polymer particles and dust, Europe, total revenue ($ m), from 2009 to
2016 44 Figure 33: Market collagen products, revenues from Europe, general ($ m), from 2009 to 2016 45
Figure 34: Facial Aesthetic Market, Europe and shares the company (% )
2009 46 Figure 35: Research Methodology GBI 70

Nuggets $ 10 million market in 2010 shocked the stout food
China Internet electronic commerce market development crazy four years, medicine has faltered development of electronic commerce, and even hard.

It is hard to access

The specificity of the drugs, state regulation of Internet pharmacies have been very strict.

Prescribed drugs are not free Internet Sales. If the sale should be Food and Drug Administration approval before being sold without a prescription and pharmaceutical companies in the retail chain can only offer consumers the Internet and drug transaction services. But, chain drug retailers want to open online pharmacies also be prohibitively hard! In addition to obtaining the qualification for the Internet and drug transaction services, but also must have on-line consultation, the consultation online, generate buy orders, contracts and other electronic-based transaction services!

The most vital is the “drug” as a special commodity, in the first grade must complete the online sales. must first obtain the “Internet drug information service certificate of qualification”, “Certificate of Internet and drug transaction services”, “two letters” rating! This “two letters” is indispensable, companies only receive this “two certificates” is named as a legitimate online pharmacies for the right to sell drugs online. Executives noted that “two certificates” that the grading policy intended to protect the interests of consumers, but also for the online sale of drugs for the regulation played a role in the escort!

Operational barriers

The development of e-commerce market in China despite the rapid, but the products involved are mainly clothes, books, home and IT products class. Traditional medicine shops online pharmacy, even if they wanted to enter the market, but most of the structures of the network technology platform due to resentment, do not know how to operate the services, I do not know how to network promotion and marketing support out. The lack of competition in the operation of e-commerce company in the Chinese market due to ignorance, lack of preparation to hardware facilities are blocking the door of online pharmacies.

From the reality of the operation of the online pharmacies you can see that, according to experts known Internet pharmacy operations, the former King Shiwen Lu describes as the network, most online pharmacy in China in May 2007 after the operation, which Beijing Health clinic operation of the first gold medal as huge pharmacy sales exceed maintain its position as the first online pharmacy in China, in addition to gold and Jing Wei as a breakthrough 10 million annual sales, the development of other online pharmacies can stand still and do not start to describe, in personal e-commerce operations and a lack of knowledge of the actual operation of the firm based on lack the spirit of the Internet is a huge problem.

No confidence in the market many companies have done />
relevant qualification certificates, but had no substantive action. Even some people reckon that online pharmacies are “not to make money to mourn”, project, online consumers can only sell nonprescription medicines, too small, and no one will to save some money in the physical side of the pharmacy and go to the web of drugs. Inadequate understanding of the market makers directly affect the progress of the online pharmacies operate.

The reason for the slow development of online pharmacies, just get “the Internet and drug transaction services B2C” certificate of Kyushu through pharmaceutical company executive, the Office of Plotting and rural residents in the analysis, said not enough emphasis on e-commerce related companies, the investment is not adequate staffing related incomplete. As the pharmaceutical industry are unique, pure e-commerce company is not certified, is generally performed in line with the best business companies pharmacy chain, Food and Drug Administration approval to carry pharmaceutical out e-commerce firms and employers usually do not know enough about the Internet industry is relatively deep, usually just give a small personal arrangements, cross the river by feeling the stones, are often inexperienced staff eventually dumped in the water, but saw a few bubbles.

In making decisions do not give importance to online pharmacies, online pharmacies are the only major pharmacy chain in the e-commerce sector. It has as many chain pharmacies online consultants eCommerce Lu Shiwen project that this organization is also seriously limited the development problem of online pharmacies.

In the second half of 2009, the online pharmacy market is an anti-day for the past four years, the trend of development.

Diabetes Market Forecast to 2015

Comprehensive Diabetes Forecast

Diabetes Market Forecast to 2015 provides teams with an in-depth analysis of the global diabetes market. Analysts place critical drug information in a relevant industrywide context. Our study details marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers – all in one, simple-to-read format.

To complement the brand and company-specific data, CEI’s analysts conducted original research with physicians and drug development/marketing executives.

Give your brand team all the diabetes data it needs to make critical product decisions!

 

Diabetes Portfolio Profiles

Amylin
Bristol-Myers Squibb
Boehringer Ingelheim
Eli Lilly
GlaxoSmithKline
Merck
Novo Nordisk
Roche
Sanofi-Aventis
Takeda

Products Profiled in Report

Traditional Insulins

Humulin
Novolin

Small-Acting Insulin Analogs

Afresa
Apidra
Humalog
Novolog
VIAject

Novel Insulins

IN-105
Oral-lyn
NN1250/SIBA
NN5401/SIAC

DPP-4 Inhibitors

Alogliptin
Dutogliptin
Galvus (includes Eucreas)
Januvia (includes Janumet)
Ondero
Onglyza

Meglitinides

Prandin

Sulfonylureas

Amaryl

Other

Ilaris
Otelixuzumab
Prochymal
Qnexa
Symlin
Teplizumab
TT-223

Adjunct Therapies

Avapro
Cozaar
Cymbalta
Lucentis
Lyrica
PF-4523655
Radiprodil/RGH-896
Zyvox

 

Data Included in the Report

Product Profile Content

Background:
Current status of drug (e.g., in development, awaiting approval, on market)
Clinical results and what they mean for the drug’s future
Drug’s current and projected competitive strength
Current and projected sales position within its class
Assessment of current and future competition
Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events
Sales projection charts through 2015
Materiality charts (drug’s percentage of company revenue) for 2009 (or first year on market) and 2015
Market Growth:

For more information kindly visit

http://www.bharatbook.com/detail.asp?id=84122&rt=Diabetes-Market-Forecast-to-2015.html

 

OR Contact us at

 

Bharat Book Bureau

207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.

Phone : +91 22 2757 8668 / 2757 9438

Fax : +91 22 2757 9131

E-mail : info@bharatbook.com

Website : www.bharatbook.com

Shcri.com: Research Report of the Third Terminal Market of Chinese Medicines, 2009

The medicine terminals refer to the places where the consumers face the medicines directly, realize the exchange between currencies and medicines and the last step for the medicines to circulate from the manufacturers to the consumers. Among the various circulation steps, the medicine terminals are the place for the manufacturers to realize the medicine sales.

 

The definition of the third terminal market is different from the first terminal market and the second terminal market. The first terminal market refers to the medicine sales in the hospitals; the second terminal market refers to the medicine sales in the OTC market, and the third terminal market refers to the medical service centers in the city communities, the town and countryside hospitals, private clinics in the countryside and the small medicine stores etc.

 

The major distribution areas of the third terminal market of Chinese medicines are the countryside and the resident areas in some towns, such as the clinics in the communities and countryside, health rooms of the enterprises and schools, rural doctors and the individual stores. With the extension of the market, the concept of the third terminal market is also extended.

 

The major medicine form in the third terminal market is the common medicine at low and medium prices or the medicine at high price because of the advertisement costs. There is no fierce competition in the medicines of the third terminal market, which is mainly bought by the clinics, health rooms and pharmacies. These medicines do not take part in the public biding, most of which are obtained in the medicine wholesales market. Although the procurement volumes are small in each time, yet most take the cash transaction and settlement, low in ventures.

 

The consumers of the third terminal market have high loyalty on the medicine brands; buy a kind of medicine successively for long time and uneasy to change brands. They have strong trust on the medicine advertisements, especially the strong media. The consumers do not have strong independent sense to choose the medicines for the first time and they mainly choose the medicines depending on the recommendations from the rural doctors and stuff of the pharmacies. The consumers are sensitive to the medicine prices and effectiveness.  In general, the consumers’ buy power in the third terminal market shows the increasing tendency.

 

With the increasing demands for the medicines in Chinese market, the scale of the third terminal market of Chinese medicines had reached 6 billion USD, which had kept rising. Owing to the competitions between the first terminal market and the second terminal market becoming a flash point day by day, the third terminal market will gradually become the place of vital importance for the medicine manufacturers and medicine circulation enterprises.

 

Meanwhile, China Research and Intelligence obtained abundant first-hand information about the third terminal market of Chinese medicines through interviews and investigations. More following information can be obtained in this report:

- Present Development Situation of Chinese Medicine Circulation Industry

- Present Development Situation of the Third Terminal Market of Chinese Medicines

- Factors affecting the Development of the Third Terminal Market of Chinese Medicines

- Target Consumers’ Behaviors of the Third Terminal Market of Chinese Medicines

- Development Trends of the Third Terminal Market of Chinese Medicines

- Major Enterprises and Their Operation of the Third Terminal Market of Chinese Medicine

 

To get more details, please visit http://www.shcri.com/reportdetail.asp?id=310

Oral Drug Delivery Market – Controlled and Sustained Release to be Major Revenue Generators This provides the key data and analyzes the major challenges and drivers for the Oral Drug Delivery Market. The report also provides in-depth analysis of unmet needs, drivers and barriers that impact the global Oral Drug Delivery Market. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It provide a comprehensive view of the Oral Drug Delivery Market. ( http://www. bharatbook. com/detail. asp?id=156728&rt=Oral-Drug-Delivery-Market-Controlled-and-Sustained-Release-to-be-Major-Revenue-Generators. html ) Scope The scope of this report includes: – Opportunities and challenges for Oral Drug Delivery Market in the pharmaceuticals industry – Market revenues and forecasts for Oral Drug Delivery Market in the global pharmaceutical industry from 2009 to 2016. – The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and China. – Technology trends in Oral Drug Delivery Market. that shape the industry – Qualitative analysis of the market drivers, barriers, future outlook and challenges for the Oral Drug Delivery Market. – Analysis of competitive landscape and the leading market players. Reasons to buy The report will enhance your choice making capability. It will allow you to: – Formulate strategies to increase your company’s growth by understanding the new growth opportunities in Oral Drug Delivery Market. – Differentiate yourself from competitors and develop new solutions for Oral Drug Delivery Market by understanding the current competitive landscape and how it is evolving to meet the increasing demands – Draft efficient strategies by understanding best practices, identifying key winners and losers and who is best positioned to take advantage of the emerging market opportunities. – Make more informed business decisions from the insightful and in-depth analysis of the market for biomanufacturing by analyzing the key technology trends that shape the growth of this market For more information kindly visit : http://www. bharatbook. com/detail. asp?id=156728&rt=Oral-Drug-Delivery-Market-Controlled-and-Sustained-Release-to-be-Major-Revenue-Generators. html Related Reports Drug Delivery Markets: Oral Deliveryhttp://www. bharatbook. com/detail. asp?id=106685&rt=Drug-Delivery-Markets-Oral-Delivery. html Innovations in Oral Solid Drug Delivery: Advances in nanotechnology, controlled formulations & peptide delivery http://www. bharatbook. com/detail. asp?id=141584&rt=Innovations-in-Oral-Solid-Drug-Delivery-Advances-in-nanotechnology-controlled-formulations-peptide-delivery. html Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668  Fax: +91 22 27579131 Email: info@bharatbook. com Website: www. bharatbook. com Follow us on twitter: http://twitter. com/3bbharatbook

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. More Information Please Click:http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. com

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Type 1 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 1 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. ScopeThe scope of the report includes: Annualized global type 1 diabetes market revenues data from 2000 to 2009, forecast forward for 7 years to 2016. Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Analysis of the current and future market competition in the global type 1 diabetes market. Key market players include Novo Nordsik, Eli Lilly, GlaxoSmithKline and Sanofi-aventis. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes. More Information Please Click:http://www. aarkstore. com/reports/Type-1-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40542. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. comKeywords: Diabetes, Drug, Type 1 Diabetes, Pipeline Analysis, Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies,  strategic competitor assessment, market characterization,  implications for future market, mechanism of action.

It is the industry analysis specialist’s new report, “Anti-Hypertension – Drug Pipeline Analysis and Market Forecasts to 2016″” is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  its team of industry experts. Scope The scope of the report includes: – Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors. – Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc. , AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis. – Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension. For More Information Please Click:http://www. aarkstore. com/reports/Anti-hypertension-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37973. html Or Call Us: 919272852585 Visit Our Blog: http://blogs. aarkstore. com

GlobalData forecasts the global candidiasis market to grow at 5. 9% annually for the next seven years to reach $2,386m by 2016. It was valued at $1,592m in 2009. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. But, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

For more information please click or add the below link to your browser:

http://www. globaldata. com/reportstore/Report. aspx?ID=Candidiasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData’s analysis has found that the current competition in the candidiasis market is strong. The current candidiasis market landscape has more than 10 marketed products. The marketed products fall under three different classes: azoles, polyenes and echinocandins. Polyenes and azoles are some of the oldest classes of drugs being used in the treatment of different types of Candida infection. The drugs from these classes are quite successful in meeting the therapeutic needs of the market and have first rate efficacy and safety profiles. Moreover, these drugs are available in different dosage forms and have high patient compliance rates. Echinocandins are available in an intravenous dosage form and have medium to high efficacy in the treatment of serious Candida infections such as invasive candidiasis, esophageal candidiasis and systemic candidiasis. Furthermore, all the products are able to cure the Candida infection in most of the cases. Because the current treatment options offer high clinical and safety standards and successfully meet the market demands, the unmet need in the candidiasis market is low.

GlobalData, the industry analysis specialist, has released its latest report, “Candidiasis – Drug Pipeline Analysis and Market Forecasts to 2016″, which provides the key data, information and analysis on the candidiasis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with candidiasis, a competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for the future market competition, and the key players in the candidiasis market.

Visit our report store: http://www. globaldata. com/reportstore

GlobalData’s report, “Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1. 8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be vital causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-mark products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes: – Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016. – Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs. – Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global NASH market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and make effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NASH market landscape? – identify, know and capitalize.

TABLE OF CONTENTS

1 Table of contents 3 1. 1 List of Tables 5 1. 2 List of Figures 5

2 Nonalcoholic Steatohepatitis Market : Market Characterization 6 2. 1 Disease Overview 6 2. 2 Symptoms 7 2. 3 Diagnosis 7 2. 3. 1 Ultrasonography 7 2. 3. 2 Computed Tomography 8 2. 3. 3 Magnetic Resonance Imaging 8 2. 3. 4 Liver function tests 8 2. 3. 5 Liver Biopsy 8 2. 4 Treatment 8 2. 5 Epidemiology 9 2. 6 Prevention 10 2. 7 Nonalcoholic Steatohepatitis Disease Market Size 11 2. 8 Nonalcoholic Steatohepatitis Market Forecast and CAGR 12 2. 9 Drivers and Barriers for the Nonalcoholic Steatohepatitis Disease Market 13 2. 9. 1 Drivers for the NASH Market 13 2. 9. 2 Barriers for the NASH Market 14 2. 10 Opportunity and Unmet Need 15 2. 11 Key Takeaway 16

3 Nonalcoholic Steatohepatitis Market : Competitive Assessment 17 3. 1 Overview 17 3. 2 Strategic Competitor Assessment 17 3. 3 Product Profile for the Major Off-Mark Marketed Products in the Nonalcoholic Steatohepatitis Market 18 3. 3. 1 Antioxidants 18 3. 3. 2 Anti-diabetic Medications 19 3. 3. 3 Anti-obesity Medications 19 3. 3. 4 Antifibrotic Medications 19 3. 4 Key Takeaway 20

4 Nonalcoholic Steatohepatitis Market : Pipeline Assessment 21 4. 1 Overview 21 4. 2 Strategic Pipeline Assessment 21 4. 2. 1 Technology Trends Analytic Framework 21 4. 3 Nonalcoholic Steatohepatitis Therapeutics – Promising Drugs under Clinical Development 23 4. 4 Molecule Profile for Promising Drugs under Clinical Development 25 4. 4. 1 DR Cysteamine (delayed release cysteamine bitartrate) 25 4. 4. 2 GS 9450 (LB84451) 26 4. 4. 3 High-Dose Ursodesoxycholic acid (HD-UDCA) 27 4. 4. 4 Byetta (exenatide) 27 4. 4. 5 EGS21 (beta glucosylceramide formulation) 28 4. 5 Nonalcoholic Steatohepatitis Market – Clinical Pipeline by Mechanism of Action 30 4. 6 Nonalcoholic Steatohepatitis – Pipeline by Clinical Phases of Development 30 4. 6. 1 Nonalcoholic Steatohepatitis Therapeutics – Phase III Clinical Pipeline 31 4. 6. 2 Nonalcoholic Steatohepatitis Therapeutics – Phase II Clinical Pipeline 31 4. 6. 3 Nonalcoholic Steatohepatitis Therapeutics – Phase I Pipeline 32 4. 6. 4 Nonalcoholic Steatohepatitis Therapeutics – Preclinical Pipeline 32 4. 7 Discontinued Drug for Nonalcoholic Steatohepatitis Disease 32 4. 8 Key Takeaway 33

5 Nonalcoholic Steatohepatitis Market : Implications for Future Market Competition 34

6 Nonalcoholic Steatohepatitis Disease Market : Future Players in the Nonalcoholic Steatohepatitis Market 36 6. 1 Introduction 36 6. 2 Raptor Pharmaceuticals 36 6. 2. 1 Company Overview 36 6. 2. 2 Gastroenterology Disease Portfolio 37 6. 2. 3 Nonalcoholic Steatohepatitis Product Portfolio 37 6. 3 Gilead Sciences 38 6. 3. 1 Company Overview 38 6. 3. 2 Gastroenterology Disease Portfolio 39 6. 3. 3 Nonalcoholic Steatohepatitis Product Portfolio 39 6. 3. 4 Axcan Pharma 40 6. 3. 5 Company Overview 40 6. 3. 6 Gastroenterology Portfolio 41 6. 3. 7 Nonalcoholic Steatohepatitis Product Portfolio 42 6. 4 Eli Lilly and Company 43 6. 4. 1 Company Overview 43 6. 4. 2 Gastroenterology Portfolio 43 6. 4. 3 Nonalcoholic Steatohepatitis Product Portfolio 43 6. 5 Enzo Biochem 44 6. 5. 1 Company Overview 44 6. 5. 2 Gastroenterology Portfolio 46 6. 5. 3 Nonalcoholic Steatohepatitis Product Portfolio 46

7 Nonalcoholic Steatohepatitis Market : Appendix 48 7. 1 Market Definitions 48 7. 2 Abbreviations 48 7. 3 Research Methodology 49 7. 3. 1 Coverage 50 7. 3. 2 Secondary Research 50 7. 3. 3 Forecasting 50 7. 3. 4 Primary Research 53 7. 3. 5 Expert Panels 53 7. 4 Contact Us 53 7. 5 Disclaimer 53 7. 6 Sources 54

Pharmaceutical report offering, “Anemia – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global anemia market. Valued the anemia market in 2009 at $10. 4 billion, indicating a Compound Annula Growth Rate (CAGR) of 8. 5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. Evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. But, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

- Annualized global anemia market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, transforming growth factor (TGF)-beta inhibitors and transferrin receptor (TfR) targetters.

- Analysis of the current and future market competition in the global anemia market. Key future market players covered are Affymax, Pharmacosmos, Amgen Inc. , Hoffmann-La Roche, Chugai – Pharmaceutical Celgene Corporation, Hoffmann-La Roche, and Johnson and Johnson.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the anemia market. For More Information Please Click:http://www. aarkstore. com/reports/Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-43090. html

Or Call Us: 919272852585

Visit Our Blog: http://blogs. aarkstore. com

The delivery of drugs using inhaled formulations is currently heavily underexploited except for the treatment of respiratory diseases. But, the large surface area offered by the lungs offers the opportunity to achieve rapid absorption of drugs from suitable inhaled formulations. It represents an opportunity to provide an effective delivery route for therapeutics, such as proteins, that are suitable for oral administration. The delivery of insulin via inhalation has been suggested as a major commercial opportunity, But, commercial success necessitates identifying stable and effective formulations, combined with a suitable, convenient, device for delivering the inhaled formulation. This report evaluates the current state of the inhaled market, examining the currently limited impact of inhaled formulations in non-respiratory segments and the dominance of the respiratory market, a major market segment, by inhaled formulations. It examines the formulations currently in development for both non-respiratory and respiratory indications as well as summarizing the inhaled formulations of new chemical entities being developed for the treatment of respiratory disease. The development of methods of delivering biological products by inhalation is highlighted as a major opportunity for growth. The value of formulation and inhaler developments is highlighted by case histories that show how they can play a key role in product lifecycle management, by building and sustaining blockbuster revenues; while not providing suitable inhalers can lead to high profile, and very costly, failure. The critical role of specialist companies in advancing technological developments with inhalers and inhaled formulations is highlighted, with the commercial opportunities that can be afforded by partnerships with such companies examined. Key features of this report•Analysis of inhaled drug market for both respiratory and non-respiratory indications. •Detailed analysis of inhaled respiratory market, both by chemical entity/formulation and by inhaler device type. •Discussion of inhaled formulations in development and assessment of opportunities offered, highlighting the current emphasis on developing new combination formulations and the challenges of developing inhaled protein formulations. Scope of this reportKey Market Issues•Inhaled therapeutics represent a significant segment of the pharmaceutical market, generating revenues of $26. 3 billion in 2008, and accounted for 78% of the revenues in the respiratory market segment. •Growth opportunities are provided by the development of inhaled formulations of new chemical entities, or by developing and establishing inhaled formulations of other classes of agent, especially protein therapeutics. •The high value of the combination steroid long acting b2 agonist segment ($10 billion) provides considerable opportunities for third parties to develop competing formulations of generically available agents. Key findings from this report• Revenues from inhaled therapeutics for non-respiratory indications are modest. • Inhaled therapeutics dominate the respiratory market segment. • There is increasing emphasis on the use of, and developing new, dry powder inhalers. • The use of nebulizers is confined to certain classes of drug and specific indications, in part due to their size and lack of portability. • Pressurized metered dose inhalers remain a key delivery option for some classes of drug. • Inhaled combination formulations represent substantially the most valuable class of inhaled therapeutics.

Key questions answered• Where are the major opportunities in the inhaled therapeutic market?• What strategies should be considered in developing inhaled products? • Which companies have an expertise in developing proprietary inhaler devices?• Which companies have expertise in developing inhaled formulations?• Where are the commercially viable opportunities for developing inhaled formulations of systemically acting agents?” 

for more information,please visit:

http://www. aarkstore. com/reports/Delivering-Opportunities-in-the-Inhalable-Drugs-Market-Innovative-formulations-and-devices-44797. html

The industry analysis specialist’s new report, “Irritable Bowel Syndrome – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.   Scope  The report provides information on the key driver and challenges of the global irritable bowel syndrome market. Its scope includes:  - Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.  - Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.  - Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global irritable bowel syndrome market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global irritable bowel syndrome market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global irritable bowel syndrome market landscape? – Identify, know and capitalize.

For more information, please contact :

http://www. aarkstore. com/reports/Irritable-Bowel-Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40308. html

Pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.  ScopeThe scope of the report includes:

Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.

Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global haemophilia market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3183/Hemophilia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeAnnualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016. Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy. Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer. For More Information Please Click :http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Angina Pectoris – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global angina pectoris market. The report identifies the key trends shaping and driving the global angina pectoris market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global angina pectoris sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global angina pectoris market revenue data from 2001 to 2009, forecast forward 7 years to 2016. – Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action includes gene therapy, combinational therapies, nitric oxide targettors, beta-1 adrenergic receptor antagonists, stem cell therapy, enzyme inhibitors, immunologic drugs, coagulation factor Xa inhibitors, adenosine A1 agonists, anticoagulants and calcium/potassium and sodium channel blockers. – Analysis of the current and future market competition in the global angina pectoris market. The key market players covered are Solvay Pharmaceuticals, Cardium Therapeutics, Inc. , Bayer Healthcare AG. , Atherogenics, Inc. , Cytokinetics, Inc, Arca Biopharma, Inc. , Anthera Pharmaceuticals, Inc, Lacer S. A and Circ Pharma. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with angina pectorisReasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global angina pectoris market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global angina pectoris market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global angina pectoris market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT025 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.   

For more information,please visit:

http://www. aarkstore. com/reports/Angina-Pectoris-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40605. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 2 diabetes market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global type 2 diabetes market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT039 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.   

For more information,please visit:

http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Anti-Obesity – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anti-obesity market. The report identifies the key trends shaping and driving the global anti- obesity market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-obesity sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global anti-obesity market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed, and emerging trends. The pipeline candidates fall under the major categories such as appetite suppressants, calorie/stout absorption inhibitors, metabolism boosters and combination drugs. – Analysis of the current and future market competition in the global anti-obesity market. Key future market players covered are Orexigen Therapeutics, Arena Pharmaceuticals, and Vivus, Inc. which holds some of the most promising molecules that have demonstrated greater efficacy or safety or both. In addition, companies such as Alizyme Therapeutics, and NeuroSearch A/S are found to be the companies with noticeable Phase III molecules. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with anti-obesity. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global anti-obesity market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anti-obesity market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global anti-obesity market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT041 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.

For more information,please visit:

http://www. aarkstore. com/reports/Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40635. html

Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1. 8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be vital causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-mark products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts. ScopeThe scope of the report includes: – Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016. – Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs. – Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH. Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global NASH market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and make effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NASH market landscape? – identify, know and capitalize. “ 

For more information, please contact :

http://www. aarkstore. com/reports/Nonalcoholic-Steatohepatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40850. html 

Pharmaceutical and healthcare report,” Allergic Conjunctivitis – Drug Pipeline Analysis and Market Forecasts to 2016″ provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-mark formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapiesScopeThe scope of the report includes:

Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.

Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global allergic conjunctivitis market landscape? – Identify, know and capitalize.

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

RNCOS has recently added a new Market Research Report titled, “Booming Generics Drug Market in India” to its report gallery. Generic drugs have become a new area of interest for pharmaceutical manufacturers. After the recession, demand for generic drugs has significantly soared due to the low cost factor. India is considered as one of the fastest growing pharmaceutical markets in the world. The introduction of product patent regime has place the industry growth on a new path. As per our new research report “Booming Generics Drug Market in India”, the generic drugs market in India is projected to grow at a CAGR of around 16. 3% during FY 2011-FY 2013.

Our team of industry experts has found that generic drugs exports from India have seen a significant surge over the last few years. The European and African countries have been added as new destinations for exports. The US and East Asian countries will remain a vital importing destinations for Indian generic products. In future, the exports are expected to pick up pace as healthcare reform in the US and other countries will inflate demand for generic drugs.

Our experts also indicate that several new trends have crept into the industry along with developments. The report provides a complete analysis on these new trends to facilitate the client know them and plot their investment strategies accordingly. The report also contains information about the regulatory environment that has done an outstanding job in the development of generic industry in India. Besides, it provides information of various industry roadblocks that need to be addressed for sustaining the growth trend. Thus, the report presents a right and unbiased picture of the industry and help the client in making investments choice.

The report is an outcome of comprehensive research and rational analysis of various segments like API and formulation drugs of Indian generic and pharmaceutical market. It provides statistical data and analysis of ongoing and future trends to facilitate a deep market understanding. The future projections are made after analyzing the current market scenario, past trends and ongoing developments in the market. A detailed overview of competitive landscape has also been included to provide a balanced research approach.

For FREE SAMPLE of this report visit: http://www. rncos. com/Report/IM256. htm

Check DISCOUNTED REPORTS on: http://www. rncos. com

WorldMarketStudy announces it Will Carry GlobalData’s Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store. Browse complete report at http://www. worldmarketstudy. com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500. html GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX. ScopeThe scope of the report includes:Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016. Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.  Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII. Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global haemophilia market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize1 Table of contents 1. 1 List of Tables 1. 2 List of Figures 2 Hemophilia Market: Market Characterization 2. 1 Overview 2. 2 Hemophilia Therapeutics Market Size 2. 3 Hemophilia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Hemophilia Therapeutics Market 2. 4. 1 Drivers for the Hemophilia Therapeutics Market 2. 4. 2 Barriers for the Hemophilia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway 3 Hemophilia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 3. 3. 1 NovoSeven 3. 3. 2 Kogenate FS 3. 3. 3 Xyntha 3. 3. 4 Advate 3. 4 Key Takeaway 4 Hemophilia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytic Framework 4. 3 Hemophilia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profile for Promising Drugs under Clinical Development 4. 4. 1 Ataluren (PTC124) 4. 4. 2 NecLip-rFVIIa (LongSeven) 4. 4. 3 rFVIII (Recombinant factor VIIa (N8)) 4. 5 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action 4. 6 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development 4. 6. 1 Hemophilia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Hemophilia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Hemophilia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Hemophilia Therapeutics – Pre-clinical Pipeline 4. 7 Key Takeaway 5 Hemophilia Therapeutics Market: Implications for Future Market Competition 6 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market 6. 1 Introduction 6. 2 PTC Therapeutics 6. 2. 1 Overview 6. 2. 2 Hemophilia Portfolio 6. 2. 3 Hemophilia Pipeline Portfolio 6. 2. 4 Ataluren (PTC124) 6. 3 Recoly N. V. 6. 3. 1 Overview 6. 3. 2 Hemophilia Portfolio 6. 3. 3 Hemophilia Pipeline Portfolio 6. 3. 4 NecLip-rFVIIa (LongSeven) 6. 4 Novo Nordisk 6. 4. 1 Overview 6. 4. 2 Hemophilia Portfolio 6. 4. 3 Hemophilia Pipeline Portfolio 6. 4. 4 rFVIII (Recombinant factor VIIa (N8)) 7 Hemophilia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 3. 1 Coverage 7. 3. 2 Secondary Research 7. 3. 3 Forecasting 7. 3. 4 Primary Research 7. 3. 5 Expert Panel Validation 7. 4 Contact Us 7. 5 Disclaimer 7. 6 Sources 1. 1 List of TablesTable 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Table 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016Table 3: Major Marketed Products Comparison in the Hemophilia Therapeutics Market, 2010 Table 4: Hemophilia Therapeutics – Most Promising Drugs Under Clinical Development, 2010 Table 5: Hemophilia Therapeutics – Phase III Clinical Pipeline, 2010 Table 6: Hemophilia Therapeutics – Phase II Clinical Pipeline, 2010 Table 7: Hemophilia Therapeutics – Phase I Clinical Pipeline, 2010 Table 8: Hemophilia Therapeutics – Pre-Clinical Pipeline,  2010 Table 9: PTC Therapeutics, Inc. – Hemophilia Pipeline Products, 2010 Table 10: Recoly N. V. – Hemophilia Pipeline Products, 2010 Table 11: Novo Nordisk – Hemophilia Pipeline Products, 20101. 2 List of FiguresFigure 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Figure 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 Figure 3: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010 Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Hemophilia Therapeutics, 2010 Figure 5: Technology Trends Analytic Framework of the Hemophilia Pipeline, 2010 Figure 6: Technology Trends Analytic Framework of the Hemophilia Therapeutics  Pipeline – Description, 2010 Figure 7: Hemophilia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010 Figure 8: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, 2010 Figure 9: Implications for Future Market Competition in the Hemophilia Therapeutics Market,  2010 Figure 10:Hemophilia Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010 Figure 11:GlobalData Methodology, 2010 Figure 12:GlobalData Market Forecasting Model, 2010View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

WorldMarketStudy announces it Will Carry GlobalData’s Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

 

Browse complete report at http://www. worldmarketstudy. com/market-report/pneumonia-drug-pipeline-analysis-market-forecasts-2016-501. html

GlobalData’s pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016″. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global pneumonia market was worth $1. 4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4. 3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market. Scope The scope of the report includes:

Reasons to buy The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

1 Table of Contents 1. 1 List of Tables 1. 2 List of Figures

2 Pnemonia Therapeutics Market: Market Characterization 2. 1 Overview 2. 2 Pneumonia Therapeutics Market Size 2. 3 Pneumonia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Pneumonia Therapeutics Market 2. 4. 1 Drivers for the Pneumonia Therapeutics Market 2. 4. 2 Barriers for the Pneumonia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway

3 Pneumonia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market 3. 3. 1 Zyvox (linezolid) 3. 3. 2 Zosyn (piperacillin and tazobactam) 3. 3. 3 Levaquin (levofloxacin) 3. 3. 4 Avelox (moxifloxacin) 3. 3. 5 Omnicef (cefdinir) 3. 3. 6 Tygacil (tigecycline) 3. 3. 7 Doribax (doripenem) 3. 4 Key Takeaway

4 Pneumonia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytical Framework 4. 3 Pneumonia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profiles for Promising Drugs under Clinical Development 4. 4. 1 Ceftaroline 4. 4. 2 Ceftobiprole medocaril 4. 4. 3 Restanza (cethromycin) 4. 4. 4 Vibativ (telavancin) 4. 5 Pneumonia Therapeutics Market – Pipeline Assessment by Mechanism of Action 4. 6 Pneumonia Therapeutics Market – Pipeline Assessment by Phase of Clinical Development 4. 6. 1 Pneumonia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Pneumonia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Pneumonia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Pneumonia Therapeutics – Preclinical Pipeline 4. 6. 5 Pneumonia Therapeutics – Discovery Pipeline 4. 7 Discontinued/Suspended Drugs for Pneumonia 4. 8 Key Takeaway

5 Pneumonia Therapeutics Market: Implications for Future Market Competition

6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market 6. 1 Forest Laboratories, Inc. 6. 1. 1 Company Overview 6. 1. 2 Ceftaroline 6. 2 Basilea Pharmaceutica 6. 2. 1 Company Overview 6. 2. 2 Ceftobiprole medocaril 6. 3 Advanced Life Sciences 6. 3. 1 Company Overview 6. 3. 2 Restanza (cethromycin) 6. 4 Theravance, Inc. 6. 4. 1 Company Overview 6. 4. 2 Vibativ (telavancin)

7 Pneumonia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 4 Coverage 7. 5 Secondary Research 7. 6 Primary Research 7. 7 Models 7. 8 Forecasts 7. 9 Expert Panels 7. 10 Sources 7. 11 GlobalData Consulting 7. 12 Contact Us 7. 13 Disclaimer1. 1 List of Tables Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010 Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010 Table 5: Cure Rates of Zyvox in Community-Bought Pneumonia due to MDRSP, 2010 Table 6: Pneumonia Therapeutics Market, Global, Most Promising Molecules under Clinical Development, May 2010 Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010 Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010 Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 20101. 2 List of Figures Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010 Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010 Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010 Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description—2010 Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010 Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010 Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010 Figure 11: GlobalData Methodology, 2010

View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

This report – The World Anesthesia Drug Market – focuses on three primary segments of anesthesia:

General Anesthesia

Local Anesthesia

Adjunctive Therapies in Anesthesia

The report covers both currently marketed and late stage development anesthesia drugs in detail. Revenues for each segment were generated using dollar and unit sales for each product. Forecasted figures were generated using a combination of projected surgical procedures, patent and exclusivity expirations, pricing trends, new developments and other factors.

The report includes statistical information for surgical procedures, incidence of conditions requiring surgery, and other relevant information. Statistical information is presented as a worldwide overview, with special emphasis on the U. S. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2009. Historical data was provided for the years 2007 and 2008, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGRs) are provided for the 2007-2009, 2007-2014 and 2009-2014 periods for each industry segment covered. Competitive analysis is provided for the year 2009 with a projected competitive analysis for 2014. The forecasted market analysis for 2009-2014 was highly influenced by the probability of approval and sales of products in late stage development, product marketing, and demographic trends.

To know more about this report & to buy a copy please visit : http://www. visionshopsters. com/product/2215/The-World-Anesthesia-Drug-Market. html

Medical tourism is a high-growth industry being driven by globalization and rising healthcare costs in developed countries. More than thirty countries in Asia, Africa and Eastern Europe are serving millions of medical tourists annually. Thailand, Singapore, Malaysia, India and Philippines are the major destinations in the Asian medical tourism market. Thailand is more well loved among Western European medical tourists for cosmetic surgery. Singapore and India specialize in complex procedures with India having a cost advantage and Singapore a technology advantage. Global economic downturn has resulted in decline in visitor numbers in Singapore and the same holds right for medical tourists also. The decline is most among Indonesian patients, but is being compensated by patients from other places such as Vietnam and the Middle East. The private healthcare market in Singapore could witness a period of slower growth due to declining medical tourists. The healthcare industry in Thailand has seen rapid growth in recent years, ahead of the country’s GDP. In Thailand, medical costs are lower than in Singapore and also, it is a much more well loved tourist destination. The cost of healthcare in Thailand is about five times lesser than it is in the US. The Malaysian government is aggressively promoting medical tourism. It has extended the visa period for health tourists from one month to six months. Major hospitals in Malaysia are targeting new markets such as Vietnam and Cambodia. India is one of the lowest cost and highest quality of all medical tourism destinations. It offers low-cost cardiovascular and orthopaedic procedures, at about one-tenth the cost of similar surgeries in the US. Taiwan provides high-quality healthcare at very competitive prices but is a slow starter. A liver transplant costs half as much in Taiwan as in Singapore. China is a key target market for Taiwanese hospitals. The Korean government is promoting the nation’s growing medical tourism industry and has set a target of 100,000 foreign patients by 2012. But, Korea is considered to be a latecomer in medical tourism industry. This report gives an overview of the medical tourism industry with focus on Asia. It discusses the major medical tourist destinations like Singapore, Thailand, Malaysia, India, Philippines, Taiwan and South Korea and their respective competitive advantages. The major healthcare organizations in Asia are also profiled in the later part of the report. Table of Contents :”1. Medical Tourism: An Overview2. Market OverviewWorldwide Market2. 1 Singapore2. 2 Thailand2. 3 Malaysia2. 4 India2. 5 Philippines2. 6 Taiwan2. 7 South Korea3. US – Outbound Medical Tourism4. Rise of Medical Tourism in Africa & Middle-East4. 1 Uganda4. 2 Tunisia4. 3 Jordan4. 4 UAE5. Profiles of Major Hospitals5. 1 Bumrungrad HospitalOverviewDecline of Foreign PatientsSwine Flu ConcernInternational Projects on HoldEffective Cost Control Programs5. 2 ParkwayOverviewLeverages Brand NameStrategy to Maintain Patient VolumeExpansion in SingaporeAdded Advantage of Regional Presence5. 3 Bangkok Dusit Medical ServicesOverviewDecline in InpatientsExpected Benefit from Tourism Turnaround5. 4 Raffles Medical GroupOverviewGroup Practice ModelDiversified Foreign Customer Base5. 5 Thomson MedicalOverviewFocus on Cost ControlExpansion of Overseas NetworkRenovation ProgramIncrease in Patient Load5. 6 KPJ HealthcareOverviewOverseas ExpansionGrowing CompetitionLow Average Revenue per Patient5. 7 Apollo HospitalsOverviewExpansion PlanList of TablesMedical Tourism Destinations by RegionPatient Demand – US Outbound Tourism (2007-12E)Comparative Cost of Major Medical Procedures by CountryParkway’s Hospitals and Medical Centers in AsiaRaffles Medical Group – Hospital Division Statistics (2006-08)Thomson Medical – Specialized ServicesList of Hospitals Owned by KPJ HealthcareExpansion Plans of Corporate Hospital Groups in IndiaList of ChartsMedical Tourism – Service NetworkWorldwide Medical Tourism Market (2006/12E)Singapore – Monthly Visitor Arrival (2008)Singapore – Population Growth by Gender (2003-07)Singapore – Medical Tourist Arrival (2006-07)Singapore – Foreign Patients by Nationality (2007)Thailand – Inflow of Foreign Patients (2000-10E)Thailand – Revenue from Foreign Patients (2005-07)Malaysia – Inflow of Foreign Patients (2006-08)Malaysia Private Healthcare – Market Share (2007)Malaysia – Foreign Patients by Nationality (2007)India – Inflow of Foreign Patients (2006-08)Philippines – Inflow of Foreign Patients (2007-12E)South Korea – Inflow of Foreign Patients (2007-12E)Tunisia – Inflow of Foreign Patients (2005-07)Jordan – Foreign Patients by Nationality (2007)Bumrungrad Hospital – Tourist Arrival Growth Vs Foreign Patient Growth (2008)Parkway Hospital – Private Patient Admission (2005-07)Bangkok Hospital – Revenue Breakdown by Thai/Foreign Patients (2008)Bangkok Dusit Medical Services – Revenue Breakdown by Hospital (2006-08)Raffles Medical Group – Foreign Patients by Nationality (2007)Thomson Medical – No. of Inpatient Admissions (2006-08)For more information please visit :http://www. aarkstore. com/reports/Medical-Tourism-Market-Report-2009-Edition-19979. html